Magnitude Biosciences is accelerating drug discovery through VivoScan®, our high-throughput in vivo phenotypic screening platform. Combining automated screening, humanised disease models, and rich phenotypic data generation, VivoScan® enables the screening of thousands of compounds in living organisms (using the nematode model, C. elegans) and delivers actionable data in a matter of weeks rather than months. The platform supports research across complex disease areas, including neurodegenerative, metabolic, and age-related disorders that do not fully recapitulate in cellular in vitro assays. Alongside VivoScan, our WormGazer® platform and portfolio of disease-specific assays support target validation, lead optimisation, mechanism of action studies, and compound characterisation across the discovery pipeline. By delivering scalable whole-organism biology in a cost-effective and time-efficient format, we enable earlier decision-making and help researchers progress the most promising candidates with greater confidence.